Evidence map›Paper›PMID 38806430›Full record

ArticleBMJ open2024

Design of the multicentre randomised controlled BENTO trial to demonstrate patient-relevant benefit of bronchoscopic lung volume reduction using thermal vapour ablation in the German healthcare system for patients with upper lobe emphysema: a study protocol.

Konstantina Kontogianni, Kaid Darwiche, Ralf Harto Huebner, Fathema Hassinger, Thomas Riemer, Felix Jf Herth, Judith Brock

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05717192 (Bronchoscopic Lung Volume Reduction in Severe Emphysema Using Thermoablation), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05717192 narecruitingnot on this map

Bronchoscopic Lung Volume Reduction in Severe Emphysema Using Thermoablation

TypeinterventionalSponsorIHF GmbH - Institut für HerzinfarktforschungRan2024 to 2027Enrolled224ConditionsEmphysema or Chronic Obstructive Pulmonary DiseaseArmsInterVapor®-System
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Konstantina KontogianniPneumology and Critical Care Medicine, Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany kkontogianni@gmail.com.ORCID 0000-0001-9798-9879
Kaid DarwicheRuhrlandklinik - West German Lung Center, University Medicine Essen, Essen, Germany.
Ralf Harto HuebnerCharite University Hospital Berlin, Berlin, Germany.
Fathema HassingerIHF GmbH - Institut für Herzinfarktforschung, Ludwigshafen am Rhein, Germany.
Thomas RiemerIHF GmbH - Institut für Herzinfarktforschung, Ludwigshafen am Rhein, Germany.
Felix Jf HerthPneumology and Critical Care Medicine, Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany.
Judith BrockPneumology and Critical Care Medicine, Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionApplication of vapour ablation as a novel approach to lung volume reduction has positive effects in patients with severe emphysema. The BENTO study is a randomised, controlled, open, multicentre trial, to assess the effects of bronchoscopic thermal vapour ablation (BTVA) in the German healthcare system. METHODS AND ANALYSIS: Patients with bilateral heterogeneous emphysema of the upper lobes in Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 3/4 will be enrolled in this trial and will receive either standard medical management alone (according to GOLD guidelines) or BTVA treatment with the InterVapor system together with standard medical management. Patients will be randomised in a 2:1 ratio (treatment group:control group). A total of 224 patients will be enrolled at 15 study sites. The primary endpoint is the change in patient-reported disease-specific quality of life, as measured by the St George's Respiratory Questionnaire for chronic obstructive pulmonary disease patients between randomisation and the 9-month follow-up visit. Secondary endpoints include adverse events, mortality, vital status, changes in lung function parameters, exercise capacity and other efficacy measures at 3, 9 and 12 months.The BENTO trial was commissioned by the German Federal Joint Committee, to demonstrate that this approach is an efficient and safe treatment option in the German healthcare system. ETHICS AND DISSEMINATION: The protocol has been approved by the lead ethics committee in Germany (Ethics Committee of the Medical Faculty of Heidelberg) and until present also by the following ethics committees: Ethics Committee of the Medical Faculty of Duisburg-Essen, Ethics Committee of the Medical Faculty of Martin-Luther-University Halle-Wittenberg, Ethics Committee of the State Medical Association of Hessen, Ethics Commission of the State Office for Health and Social Affairs of the State of Berlin, Ethics Committee of the Medical Faculty of Greifswald. The results will be published in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: NCT05717192.

Indexed as

BronchoscopyPneumonectomyPulmonary EmphysemaQuality of LifeAblation TechniquesFemaleGermanyHumansMaleMulticenter Studies as TopicPulmonary Disease, Chronic ObstructiveRandomized Controlled Trials as TopicTreatment OutcomeBronchoscopyEmphysemaThoracic medicine

Identifiers

PMID38806430
PMCPMC11138281

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.